Literature DB >> 2368893

Steady-state pharmacokinetics of interpleural bupivacaine in patients after cholecystectomy.

H Kastrissios1, E J Triggs, G A Mogg, D Sainsbury, J Higbie, K Leow, J Sidhu.   

Abstract

Venous plasma concentrations of bupivacaine were determined in eight cholecystectomy patients following multiple interpleural bolus instillations of bupivacaine 20 ml 0.5% with adrenaline (5 mg/l) administered at six- to eight-hour intervals. The mean steady-state peak plasma concentration was 2.3 mg/l (range 1.2-3.1 mg/l); however, in three of the eight patients peak plasma concentrations were greater than 3 mg/l. The mean accumulation ratio was found to be 1.6 (range 0.99-2.49), with steady-state occurring within the first 24 hours of drug administration. Mean apparent systemic plasma clearance was 0.16 +/- 0.07 l/kg/h with a mean terminal half-life of 5.8 +/- 2.3 hours measured at steady-state, values which were not significantly different (P greater than 0.05) from those values obtained following single interpleural bolus dose administration.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2368893     DOI: 10.1177/0310057X9001800207

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  3 in total

1.  Plasma concentrations of bupivacaine after wound infiltration of an 0.5% solution after inguinal herniorrhaphy: a preliminary study.

Authors:  H Kastrissios; E J Triggs; F Sinclair; P Moran; M Smithers
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

2.  Successful treatment of local anaesthetic toxicity using intralipid 20% emulsion following intrathoracic bupivacaine overdose in a cat.

Authors:  Sarah Caulfield; Erica Tinson; Rachael Birkbeck
Journal:  JFMS Open Rep       Date:  2022-06-23

3.  The disposition of bupivacaine following a 72 h interpleural infusion in cholecystectomy patients.

Authors:  H Kastrissios; E J Triggs; G A Mogg; J W Higbie
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.